The Walker B motif of the second nucleotide-binding domain (NBD2) of CFTR plays a key role in ATPase activity by the NBD1-NBD2 heterodimer.

CFTR (cystic fibrosis transmembrane conductance regulator), a member of the ABC (ATP-binding cassette) superfamily of membrane proteins, possesses two NBDs (nucleotide-binding domains) in addition to two MSDs (membrane spanning domains) and the regulatory 'R' domain. The two NBDs of CFTR have been modelled as a heterodimer, stabilized by ATP binding at two sites in the NBD interface. It has been suggested that ATP hydrolysis occurs at only one of these sites as the putative catalytic base is only conserved in NBD2 of CFTR (Glu1371), but not in NBD1 where the corresponding residue is a serine, Ser573. Previously, we showed that fragments of CFTR corresponding to NBD1 and NBD2 can be purified and co-reconstituted to form a heterodimer capable of ATPase activity. In the present study, we show that the two NBD fragments form a complex in vivo, supporting the utility of this model system to evaluate the role of Glu1371 in ATP binding and hydrolysis. The present studies revealed that a mutant NBD2 (E1371Q) retains wild-type nucleotide binding affinity of NBD2. On the other hand, this substitution abolished the ATPase activity formed by the co-purified complex. Interestingly, introduction of a glutamate residue in place of the non-conserved Ser573 in NBD1 did not confer additional ATPase activity by the heterodimer, implicating a vital role for multiple residues in formation of the catalytic site. These findings provide the first biochemical evidence suggesting that the Walker B residue: Glu1371, plays a primary role in the ATPase activity conferred by the NBD1-NBD2 heterodimer.

[1]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[2]  Paola Vergani,et al.  The ABC protein turned chloride channel whose failure causes cystic fibrosis , 2006, Nature.

[3]  J. Fulghum,et al.  Nucleotide-binding Domains of Cystic Fibrosis Transmembrane Conductance Regulator, an ABC Transporter, Catalyze Adenylate Kinase Activity but Not ATP Hydrolysis* , 2006, Journal of Biological Chemistry.

[4]  S. Cole,et al.  Substrate recognition and transport by multidrug resistance protein 1 (ABCC1) , 2006, FEBS letters.

[5]  R. Callaghan,et al.  The translocation mechanism of P‐glycoprotein , 2006, FEBS letters.

[6]  Jue Chen,et al.  ATP hydrolysis is required to reset the ATP-binding cassette dimer into the resting-state conformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. R. Lugo,et al.  New Insights into the Drug Binding, Transport and Lipid Flippase Activities of the P-Glycoprotein Multidrug Transporter , 2005, Journal of bioenergetics and biomembranes.

[8]  A. Nairn,et al.  Control of the CFTR channel's gates. , 2005, Biochemical Society transactions.

[9]  C. Férec,et al.  Nucleotide binding domains of human CFTR: a structural classification of critical residues and disease-causing mutations. , 2005, Cellular and Molecular Life Sciences CMLS.

[10]  A. Evagelidis,et al.  Phosphorylation of CFTR by PKA promotes binding of the regulatory domain , 2005, The EMBO journal.

[11]  R. Callaghan,et al.  The coupling mechanism of P‐glycoprotein involves residue L339 in the sixth membrane spanning segment , 2005, FEBS letters.

[12]  L. Schmitt,et al.  Functional characterization and ATP-induced dimerization of the isolated ABC-domain of the haemolysin B transporter. , 2005, Biochemistry.

[13]  Lutz Schmitt,et al.  H662 is the linchpin of ATP hydrolysis in the nucleotide‐binding domain of the ABC transporter HlyB , 2005, The EMBO journal.

[14]  Paola Vergani,et al.  CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains , 2005, Nature.

[15]  A. Nairn,et al.  Preferential Phosphorylation of R-domain Serine 768 Dampens Activation of CFTR Channels by PKA , 2005, The Journal of general physiology.

[16]  M. Welsh,et al.  Normal gating of CFTR requires ATP binding to both nucleotide-binding domains and hydrolysis at the second nucleotide-binding domain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Huan,et al.  A Heteromeric Complex of the Two Nucleotide Binding Domains of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mediates ATPase Activity* , 2004, Journal of Biological Chemistry.

[18]  L. D. Howell,et al.  Stimulatory and inhibitory protein kinase C consensus sequences regulate the cystic fibrosis transmembrane conductance regulator , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Canhui Li,et al.  CFTR directly mediates nucleotide‐regulated glutathione flux , 2003, The EMBO journal.

[20]  F. Sharom,et al.  Transition state P-glycoprotein binds drugs and modulators with unchanged affinity, suggesting a concerted transport mechanism. , 2003, Biochemistry.

[21]  John F Hunt,et al.  Cooperative, ATP-dependent Association of the Nucleotide Binding Cassettes during the Catalytic Cycle of ATP-binding Cassette Transporters* , 2002, The Journal of Biological Chemistry.

[22]  Douglas C. Rees,et al.  The E. coli BtuCD Structure: A Framework for ABC Transporter Architecture and Mechanism , 2002, Science.

[23]  A. Powe,et al.  Mutation of Walker‐A lysine 464 in cystic fibrosis transmembrane conductance regulator reveals functional interaction between its nucleotide‐binding domains , 2002, The Journal of physiology.

[24]  K. Linton,et al.  The xyz of ABC Transporters , 2001, Science.

[25]  J. Riordan,et al.  Differential Interactions of Nucleotides at the Two Nucleotide Binding Domains of the Cystic Fibrosis Transmembrane Conductance Regulator* , 2001, The Journal of Biological Chemistry.

[26]  L. Huan,et al.  Perturbation of the Pore of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibits Its ATPase Activity* , 2001, The Journal of Biological Chemistry.

[27]  C. Higgins,et al.  ABC transporters: physiology, structure and mechanism--an overview. , 2001, Research in microbiology.

[28]  M. Welsh,et al.  Regulation of the Cystic Fibrosis Transmembrane Conductance Regulator Cl− Channel by Its R Domain* , 2001, The Journal of Biological Chemistry.

[29]  John A. Tainer,et al.  Structural Biology of Rad50 ATPase ATP-Driven Conformational Control in DNA Double-Strand Break Repair and the ABC-ATPase Superfamily , 2000, Cell.

[30]  J. Riordan,et al.  Influence of phosphorylation by protein kinase A on CFTR at the cell surface and endoplasmic reticulum. , 1999, Biochimica et biophysica acta.

[31]  Y. Wang,et al.  Walker mutations reveal loose relationship between catalytic and channel-gating activities of purified CFTR (cystic fibrosis transmembrane conductance regulator). , 1999, Biochemistry.

[32]  E. Thompson,et al.  Optimal ligand binding by the recombinant human glucocorticoid receptor and assembly of the receptor complex with heat shock protein 90 correlate with high intracellular ATP levels in Spodoptera frugiperda cells , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[33]  J. Rommens,et al.  ATPase Activity of the Cystic Fibrosis Transmembrane Conductance Regulator* , 1996, The Journal of Biological Chemistry.

[34]  J. Riordan,et al.  Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites. , 1993, The Journal of biological chemistry.

[35]  L. Tsui,et al.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.

[36]  J. Riordan,et al.  Assembly of functional CFTR chloride channels. , 2005, Annual review of physiology.

[37]  C. Bear,et al.  Molecular basis for the chloride channel activity of cystic fibrosis transmembrane conductance regulator and the consequences of disease-causing mutations. , 2004, Current topics in developmental biology.

[38]  J. Mornon,et al.  Nucleotide-binding domains of human cystic fibrosis transmembrane conductance regulator: detailed sequence analysis and three-dimensional modeling of the heterodimer , 2003, Cellular and Molecular Life Sciences CMLS.